The use of GLP-1 weight loss medications is altering consumer habits and increasing demand for lean meats and grains in Brazil [1, 3].
This shift in eating patterns affects the Brazilian agribusiness sector as users of these medications seek high-protein and low-calorie alternatives. Because these drugs reduce appetite, consumers are moving away from traditional calorie-dense foods toward functional nutrition [1, 3].
The trend began to gain momentum in 2024 [3]. The impact has accelerated this year following a significant policy change in the public health sector. On March 18, 2026, Rio de Janeiro became the first city to offer Ozempic through the Sistema Único de Saúde (SUS) [2].
Public availability of the drug expands the demographic of users beyond those who can afford private prescriptions. This expansion likely increases the scale of the shift in food procurement, as more citizens transition to diets rich in lean proteins, and functional grains [2].
While the trend is currently highlighted in Brazil, the global scale of such medications is substantial. For context, approximately 1.6 million people in the United Kingdom used weight loss injections in 2024 [3].
The Brazilian agricultural market is responding to these changes by adjusting the production and distribution of specific food groups. The demand for protein-rich foods and grains is rising as users prioritize nutrient density over volume [1, 3].
“The use of GLP-1 weight loss medications is altering consumer habits and increasing demand for lean meats and grains in Brazil.”
The integration of GLP-1 agonists into public health systems like the SUS marks a transition from these drugs being luxury lifestyle products to standardized medical treatments. This systemic shift creates a predictable macroeconomic ripple effect, forcing the agribusiness sector to pivot toward functional foods and lean proteins to meet the changing biological requirements of a growing patient population.
